Skip to main content
Premium Trial:

Request an Annual Quote

Marina Closes Cequent Facility, Consolidates R&D in Washington


Marina Biotech announced last week that it has closed its Cambridge, Mass., operations and is consolidating all of its research and development activities at its Bothell, Wash. headquarters.

The company acquired the Massachusetts facility through its 2010 acquisition of Cequent Pharmaceuticals (GSN 4/1/2010).

Marina said that the move would not affect development of Cequent's transkingdom RNAi technology, which will continue in Washington, and that its phase I program for CEQ508, a tkRNA-based treatment for familial adenomatous polyposis, will be unchanged.

Marina President and CEO Michael French said in an e-mail that the company transitioned three positions from the Cambridge facility to Bothell, but added that certain positions associated with maintaining the bacterial component of the tkRNA technology were not relocated since Marina already has that core capability in Washington.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.